Upgrade Your Browser
We no longer support this version of your browser.
We recommend that you upgrade to the latest version of Internet Explorer, Firefox, Chrome or Safari to improve your security and experience using this website.
Return to the course you were viewing
You'll see the new injectable, Xultophy, for type 2 diabetes.
Xultophy (ZUL-toh-fye) combines the long-acting "basal" insulin, Tresiba (insulin degludec) and the GLP-1 agonist, Victoza (liraglutide).
Think of Xultophy as similar to Soliqua, which is a combo of Lantus (insulin glargine) and Adlyxin (lixisenatide).
Pharmacy Technician's Letter includes:
Already a subscriber? Log in
Volume pricing available. Get a quote